The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
From medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact Areas
Explore stories, news, insights, and data across articles, videos, and podcasts.
view all content types
in Israel and Europe for research on artificial intelligence
students
of all universities in the world*
The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Explore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATSATS is a community of supporters, innovators, and champions of possibility united by one mission: transforming Israel and the world through science and discovery.
Learn MoreFor more than 100 years, the Technion has been Israel's technological engine and leading driver of innovation, technology, and entrepreneurship, transforming ideas into impact.
Learn More
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreFrom medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact AreasExplore stories, news, insights, and data across articles, videos, and podcasts.
view all content typesExplore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATS
Dr. Meiri’s lab, the largest of its kind in academia with 44 researchers, investigates the therapeutic potential of cannabinoids, the naturally-occurring chemicals found in the cannabis plant. Researchers work on a variety of projects in the lab with its main focus on how cannabinoids affect various types of cancer, epilepsy, and diabetes.
A man on a mission, Dr. Meiri aims to understand the cannabis plant thoroughly enough so that a doctor can prescribe the right treatment at the right dosage for a particular patient. To that end, he collaborates with cannabis growers, clinicians, major manufacturers, and distributors of medical cannabis to identify almost every strain of marijuana grown in Israel, matching them to the diseases they affect. He has launched the Database Project, which exhaustively profiles compounds given to Israel’s 60,000 medical marijuana patients. Dr. Meiri also helps Israel’s Ministry of Health advance its understanding of cannabis usage.
His academic background is highly diverse. Dr. Meiri holds a master’s degree in biochemistry and a doctoral degree in plant biotechnology from Tel Aviv University. He conducted his postdoctoral work at the Ontario Cancer Institute before joining the Technion in 2014.
As universities across Israel prepare to begin the new academic year, there is an ever-present sense of resilience among staff, faculty and students. However, Israeli universities are not immune to the same global trends and challenges affecting their counterparts in the United States, particularly the rapid development and adoption of AI. The academic year is […]
Before Israel became a state, the Technion was educating the people who would help build it. As the country grew, its challenges called for new knowledge — and generations of Technion minds answered. This short film follows that journey, from the engineers who helped construct Israel’s infrastructure to the researchers whose discoveries strengthened its security, […]
At the Technion, Israel Institute of Technology, the future often begins with a deceptively simple question: What can we do today that we could not do before? “Science and engineering have never been about yesterday’s tasks. They’ve always been about the future,” said Prof. Lihi Zelnik-Manor, vice president of External Relations and Resource Development at […]
Stay on top of the latest breaking scientific discoveries from Israel and the Technion. Subscribe to the ATS newsletter.